Drugs / AR882
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04646889 | Jan 2021 → Jun 2022 | impaired renal function disease | Arthrosi Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04508426 | Jul → Aug 2020 | — | Arthrosi Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04314986 | Jun → Sep 2019 | — | Arthrosi Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04347005 | Jan → Jul 2019 | — | Arthrosi Therapeutics | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07116746 | Dec 2025 → Nov 2026 expected | gout | Arthrosi Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05253833 | Aug 2022 → Aug 2024 | gout | Arthrosi Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT05119686 | Nov 2021 → Nov 2022 | gout | Arthrosi Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT04155918 | Feb → Sep 2020 | gout | Arthrosi Therapeutics | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06603142 | Apr 2024 → Apr 2026 overdue | gout | Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06846515 | Mar 2025 → Sep 2026 expected | gout | Arthrosi Therapeutics | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06439602 | Jun 2024 → Mar 2026 | gout | Arthrosi Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR882 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04155918 ↗ |
| Route | Oral | “Orally Administered” NCT04508426 ↗ |